Medical Therapeutics

Pow.Bio

Brief Description

Pow.Bio provides intelligent fermentation services for industrial and synthetic biology. The company has built an AI platform that rapidly identified better-performing process conditions, increasing output 2–3x from existing infrastructure within just 100 days. The company's services combine continuous fermentation with advanced control methodology to quickly optimize the fermentation process and deliver high yields at low cost. The scale runs from 1-100 liter capacity for bacteria, yeast, and filamentous fungi. The first-of-its-kind fermentation technology solves the...

Tenaya Therapeutics

Brief Description

Tenaya Therapeutics is shaping the future of heart disease treatment driven by a mission to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. The company was spun out of a new method for creating three-dimensional human heart tissue from stem cells, developed in a collaboration between UC Berkeley Professor of Materials Science...

Sift Biosciences

Brief Description

Sift Biosciences supercharges existing cancer therapies by leveraging artificial intelligence and high-throughput cellular screening to discover and design immunotherapy boosters that significantly extend cancer patient survival. The company was co-founded by Yue Clare Lou (BS ’18 Microbial Biology; PhD ’23 Microbiology) and Maddie Williams (PhD student '23-present, Molecular & Cell Biology) to commercize technology developed during their doctoral research at UC Berkeley.

Timeline 2024. Company founded Inventors

Yue "Clare" Lou, Madeline Dee...

CryoVox Technologies

Brief Description

Crovox Technologies is developing new tools for the mass manufacturing of 3D cell cultures.

Timeline 2024. Company founded Inventors

Boris Rubinsky, Michal Adamkievicz, Ze'ev Shaked

KaRNAteq, Inc.

Brief Description

KaRNATeq develops tools for RNA sequencing that are the next step forward in genomics. The enzymes developed by the company enable doctors and scientists to capture more information at reduced cost.

Timeline 2019. Company founded Inventors

Kathleen Collins, Heather Upton

Renovis, Inc.

Brief Description

Renovis, Inc. was a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The company used molecular biology, medicinal chemistry, in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics, toxicology, and informatics to identify and select small molecule drug candidates that meet stringent standards for development.

Renovis was founded by UC Berkeley and UCSF faculty. Founder Corey Goodman was the UC Berkeley chair of neurobiology, head of the neurobiology division, and co-founder and director of the Wills...

MuscleMatrix

Brief Description

MuscleMatrix is developing a hydrogel that could change how medics treat traumatic injuries on the battlefield, as well as revolutionize surgical repairs for civilians with soft tissue injuries. Traumatic and surgical injuries of soft tissue that involve underlying skeletal muscle remain one of the greatest challenges to tissue reconstruction. Severe injuries, such as those involving the loss of a substantial portion of muscle tissue, are not capable of healing on their own and are referred to as volumetric muscle loss (VML) injuries. By definition, VML results in...

Tessera Therapeutics, Inc.

Brief Description

Developer of gene writing technology designed to permanently make small and large alterations to the human genome. The company's technology helps scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, enabling healthcare providers to cure their patients and improve their lives.

Tessera Scientific Advisory Board Member David Schaffer co-invented the company's foundational technology as UC Berkeley Professor of Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell...

Lyterian Therapeutics, Inc.

Brief Description

Lyterian Therapeutics is committed to developing transformative medicines for patients by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets. Lyterian is derived from λυτήριος or lutḗrios, which means termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. Lyterian Therapeutics medicines are inspired by the logic that orchestrates homeostatic equilibria and drives healing.

Timeline 2022....

Elenae Therapeutics

Brief Description

Applying antisense oligonucleotide technology to target coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

Timeline 2021. Company founded Inventors

Anders Naar, Sakari Kauppinen